Inhibitec

Inhibitec Anticuerpos, a pioneering biotech startup with a therapy against chronic autoimmune/inflammatory diseases in pre-clinical phase, presents its project to investors at the 20th Investor Round organized by the Fundación Innovación y Desarrollo (Innovation and Development Foundation, FIDBAN). It should be noted that its technology is protected by a patent owned by the Superior Council for Scientific Research (CSIC, Consejo Superior de Investigaciones Científicas) and the University of Cantabria (UC). It is also worth highlighting that the therapy offered by Inhibitec Antibodies is based on an innovative monoclonal antibody that targets BAMBI (BMP and activin membrane inhibitor). This patented dual approach aims to address the problem affecting the 40% of patients who do not respond adequately to current biologic treatments.